" "@en . . . "2-Amino-9-(2-hydroxy-1-hydroxymethyl-ethoxymethyl)-1,9-dihydro-purin-6-one"@en . . . . . . . . . . "For induction and maintenance in the treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients, including patients with acquired immunodeficiency syndrome (AIDS). Also used in the treatment of severe cytomegalovirus (CMV) disease, including CMV pneumonia, CMV gastrointestinal disease, and disseminated CMV infections, in immunocompromised patients."@en . . "2-(6-Amino-purin-9-ylmethoxy)-propane-1,3-diol"@en . . . "\"DrugSyn.org\":http://www.drugsyn.org/Ganciclovir.htm"@en . . . . . . . . "Human Herpes Virus"@en . "Take with food, food increases bioavailability."@en . "Oral, mouse LD₅₀: > 2g/kg. Intravenous, dog LD₅₀: > 150mg/kg. Symptoms of overdose include irreversible pancytopenia, worsening GI symptoms, and acute renal failure. Suspected cancer agent."@en . "An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections. [PubChem]"@en . . "Poorly absorbed systemically following oral administration. Bioavailability under fasting conditions is approximately 5%, and when administered with food, 6 to 9% (about 30% with a fatty meal)."@en . . "82410-32-0"@en . . . . "GA2"@en . . . . . . . . . "2-amino-9-((1,3-Dihydroxypropan-2-yloxy)methyl)-9H-purin-6-ol"@en . . . . "2-amino-9-((1,3-Dihydroxypropan-2-yloxy)methyl)-1H-purin-6(9H)-one"@en . . . . . "Ganciclovirum"@en . . . . . . "9-((2-Hydroxy-1-(hydroxymethyl)ethoxy)methyl)guanine"@en . . . . . . . . . " "@en . . . . "9-[(1,3-dihydroxy-2-propoxy)methyl]guanine"@en . . "1 to 2%"@en . "Ganciclovir"@en . . "2-amino-9-((1,3-Dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one"@en . "* 0.74 \u00B1 0.15 L/kg"@en . . "* 128 +/- 63 mL/min [Patients with Renal Impairment (Clcr=50-79 mL/min)] * 57+/- 8 mL/min [Patients with Renal Impairment (Clcr=25-49 mL/min)] * 30 +/- 13 mL/min [Patients with Renal Impairment (Clcr<25 mL/min)] * 4.7+/- 2.2 mL/min/kg [pediatric patients, aged 9 months to 12 years]"@en . . "Ganciclovir"@en . . "approved"@en . . . "2.5 to 3.6 hours (mean 2.9 hours) when administered intravenously in adults. 3.1 to 5.5 hours when administered orally in adults. Renal function impairment causes a marked increase in half life (9 to 30 hours intravenously, 15.7 to 18.2 hours orally)."@en . . . . . . "Renal excretion of unchanged drug by glomerular filtration and active tubular secretion is the major route of elimination of ganciclovir."@en . . . "2-amino-9-(2-Hydroxy-1-hydroxymethylethoxymethyl)-6,9-dihydro-1H-6-purinone"@en . "investigational"@en . "Ganciclovir's antiviral activity inhibits virus replication. This inhibitory action is highly selective as the drug must be converted to the active form by a virus-encoded cellular enzyme, thymidine kinase (TK). TK catalyzes phosphorylation of ganciclovir to the monophosphate, which is then subsequently converted into the diphosphate by cellular guanylate kinase and into the triphosphate by a number of cellular enzymes. In vitro, ganciclovir triphosphate stops replication of herpes viral DNA. When used as a substrate for viral DNA polymerase, ganciclovir triphosphate competitively inhibits dATP leading to the formation of 'faulty' DNA. This is where ganciclovir triphosphate is incorporated into the DNA strand replacing many of the adenosine bases. This results in the prevention of DNA synthesis, as phosphodiester bridges can longer to be built, destabilizing the strand. Ganciclovir inhibits viral DNA polymerases more effectively than it does cellular polymerase, and chain elongation resumes when ganciclovir is removed."@en . . "Gancyclovir"@en . . .